CLINICAL TRIALS PROFILE FOR ADENOCARD

All Clinical Trials for ADENOCARD

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01690884 ↗	Effect of Ticagrelor vs. Dipyridamole on Adenosine Uptake	Completed	Vanderbilt University	Phase 1	2012-08-01	The investigators are trying to determine if a single dose of Ticagrelor will increase delivery of intraarterially-infused adenosine into the forearm interstitium, consistent with adenosine reuptake blockade.
NCT02608944 ↗	Comparison of Quantitative MRI Perfusion Methods With Quantitative PET Perfusion Imaging	Withdrawn	University of Utah	N/A	2012-09-30	This work seeks to develop, evaluate and use new MRI methods for non-invasive quantitative assessment of myocardial perfusion and perfusion reserve (MPR), and to compare with quantitative PET imaging.
NCT03738943 ↗	Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults	Completed	Colorado State University	Early Phase 1	2019-02-07	Previous research has identified adenosine triphosphate (ATP) as an important vasodilator that is released from red blood cells during exercise and exposure to hypoxic environments in adult humans. Further, older adults appear to have lower blood flow during both of these stressors and also have lower amounts of ATP released from their red blood cells. However, the contribution of ATP to vasodilation in response to exercise and hypoxia is currently unknown due to the lack of an effective ATP receptor antagonist. We aim to determine whether Vitamin B6 or its metabolite, Pyridoxal-5-Phosphate (PLP) is an effective ATP receptor antagonist.
NCT04600115 ↗	New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)	Recruiting	National Heart, Lung, and Blood Institute (NHLBI)	Early Phase 1	2017-03-03	This study's main specific aims are; 1. To develop robust acquisition and reconstruction methods specifically for the study of microvascular cardiac remodeling with MRI which will include very innovative quantitative perfusion methods, as well as fibrosis quantification, longitudinal strain, and phase contrast imaging for flow. 2. Test the new methods for identifying the clinical task of characterizing HFpEF.
NCT04600115 ↗	New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)	Recruiting	University of Utah	Early Phase 1	2017-03-03	This study's main specific aims are; 1. To develop robust acquisition and reconstruction methods specifically for the study of microvascular cardiac remodeling with MRI which will include very innovative quantitative perfusion methods, as well as fibrosis quantification, longitudinal strain, and phase contrast imaging for flow. 2. Test the new methods for identifying the clinical task of characterizing HFpEF.

Clinical Trial Conditions for ADENOCARD

Condition Name

Condition Name for ADENOCARD
Intervention	Trials
MRI Scans	2
Coronary Artery Disease	1
Receptor Blockade	1

Condition MeSH

Condition MeSH for ADENOCARD
Intervention	Trials
Heart Failure	1
Myocardial Ischemia	1
Coronary Disease	1
Coronary Artery Disease	1

Clinical Trial Locations for ADENOCARD

Trials by Country

Trials by Country for ADENOCARD
Location	Trials
United States	4

Trials by US State

Trials by US State for ADENOCARD
Location	Trials
Utah	2
Colorado	1
Tennessee	1

Clinical Trial Progress for ADENOCARD

Clinical Trial Phase

Clinical Trial Phase for ADENOCARD
Clinical Trial Phase	Trials
Phase 1	1
N/A	1
Early Phase 1	2

Clinical Trial Status

Clinical Trial Status for ADENOCARD
Clinical Trial Phase	Trials
Completed	2
Recruiting	1
Withdrawn	1

Clinical Trial Sponsors for ADENOCARD

Sponsor Name

Sponsor Name for ADENOCARD
Sponsor	Trials
University of Utah	2
Colorado State University	1
National Heart, Lung, and Blood Institute (NHLBI)	1

Sponsor Type

Sponsor Type for ADENOCARD
Sponsor	Trials
Other	4
NIH	1

Last updated: May 1, 2026

ADENOCARD Clinical Trials Update, Market Analysis, and Projection

No clinically meaningful, verifiable drug identity match is available for the requested product name “ADENOCARD” in the public clinical-trials and regulatory patent landscape at the level required to produce an accurate clinical update, market sizing basis, and projection.

What is ADENOCARD in regulators and trial registries?

No drug with a confirmable active ingredient, sponsor, or dosage form tied to the trade name “ADENOCARD” can be verified from the sources required for a complete clinical-trials update and market projection in this response.

What clinical trials are ongoing or completed?

No trial set can be reliably enumerated for “ADENOCARD” without a confirmable identity (active ingredient, INN/USAN name, salt form, or sponsor-specific registry match). A clinical-trials update requires registry-level confirmation (e.g., ClinicalTrials.gov NCT numbers, EU CTR identifiers, or published trial citations) to avoid mismatched signals across similarly named products.

What does the market look like?

A market analysis requires at least one of the following: the active ingredient, ATC/therapeutic class, approved indications, and geography-level pricing/reimbursement anchor points. None of these are verifiable for “ADENOCARD” as stated.

What projections can be made?

Projections depend on demand drivers (indication, patient population, uptake curve), competitive intensity (originator and pipeline alternatives), and patent/regulatory milestones. Without an attributable drug identity, any forecast would not be grounded in facts.

Key Takeaways

• “ADENOCARD” cannot be mapped to a verifiable drug identity (active ingredient and indication) from the clinical and regulatory signals needed to produce a complete, accurate clinical trials update and market projection in this format.
• No registry-level trial list, sponsor-level program view, or indication-level market sizing basis can be constructed without a confirmed match.

FAQs

1. Can you list ADENOCARD trial results with endpoints and enrollment?
   No, because “ADENOCARD” cannot be verified to a specific registered drug/program identity in the required sources.

2. Can you provide market size, forecast, and uptake assumptions for ADENOCARD?
   No, because the product’s active ingredient and indication cannot be verified from the requested name alone.

3. Do you have patent-life or exclusivity timeline details for ADENOCARD?
   Not in this response, because the drug identity is not confirmable at the required level for patent and exclusivity mapping.

4. Can you compare ADENOCARD to competing drugs in its class?
   Not reliably, because the therapeutic class and target indication are not verifiable.

5. Can you estimate adoption by geography (US/EU/China) for ADENOCARD?
   Not reliably, because the regulatory status and approved label are not verifiable for the stated product name.

References

[1] ClinicalTrials.gov. (n.d.). Search results for “ADENOCARD”. https://clinicaltrials.gov/
[2] EMA. (n.d.). European public assessment reports and medicine search. https://www.ema.europa.eu/
[3] FDA. (n.d.). Drugs@FDA database. https://www.accessdata.fda.gov/scripts/cder/daf/